Tempo Bioscience

Tempo Bioscience is a private, early-stage biotech firm founded in 2020, specializing in the development of advanced cell-based assay technologies and disease models. The company leverages human primary cells, iPSCs, and 3D culture techniques to create patient-relevant in vitro systems for drug discovery and preclinical research, with a focus on complex biological barriers and organ-specific toxicity. Operating primarily as a platform and services provider, Tempo supports pharmaceutical and biotech partners in adopting New Approach Methodologies (NAMs) to reduce reliance on animal models. Its current expansion into human liver and blood-brain-barrier models positions it in the growing market for human-relevant predictive assays.

Integrated platform for developing human-relevant cell-based disease models. Utilizes human primary cells, induced pluripotent stem cells (iPSCs), gene editing, and advanced 2D/3D culture systems (including organoids). Specializes in functional assays for biological barriers, including Transwell setups and Transepithelial/Endothelial Electrical Resistance (TEER) measurements to assess integrity and permeability.

Tempo operates in the competitive field of advanced in vitro models, competing with organ-on-a-chip companies like Emulate and Mimetas, stem cell and organoid specialists such as Stemcell Technologies and Cellesce, and large reagent suppliers offering 3D culture products. Differentiation will hinge on the sophistication and predictive validity of its specific models (e.g., BBB, liver), its service model, and its ability to form deep partnerships with drug developers.